Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 7, Pages 1991
Publisher
MDPI AG
Online
2020-07-22
DOI
10.3390/cancers12071991
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
- (2019) Fu-Ju Chou et al. EBioMedicine
- Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence
- (2019) Lorenzo Livi et al. TUMORI
- Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway
- (2019) Konjeti R. Sekhar et al. PLoS One
- Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair
- (2019) Wenhao Zhang et al. Cancers
- Exploring the Role of Enzalutamide in Combination with Radiation Therapy: AnIn VitroStudy
- (2018) LUCA TRIGGIANI et al. ANTICANCER RESEARCH
- Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
- (2018) Zhong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
- (2018) Kasey Jividen et al. BMC CANCER
- Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells
- (2017) Maryam Ghashghaei et al. PROSTATE
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling
- (2017) Styliani Karanika et al. Cell Reports
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model
- (2016) Daisuke Nakata et al. PROSTATE
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
- (2015) M. Kato et al. CLINICAL CANCER RESEARCH
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Hormone and Radiotherapy versus Hormone or Radiotherapy Alone for Non-metastatic Prostate Cancer: A Systematic Review with Meta-analyses
- (2014) M. Schmidt-Hansen et al. CLINICAL ONCOLOGY
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of the androgen receptor splicing in prostate cancer cells
- (2013) L L Liu et al. ONCOGENE
- Repair of Double-Strand Breaks by End Joining
- (2013) K. K. Chiruvella et al. Cold Spring Harbor Perspectives in Biology
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
- (2012) Ketki Karanam et al. MOLECULAR CELL
- Androgen receptor and its splice variants in prostate cancer
- (2011) Simon Haile et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Radiorecurrent Prostate Cancer: An Emerging and Largely Mismanaged Epidemic
- (2011) J. Stephen Jones EUROPEAN UROLOGY
- Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
- (2011) Christopher U. Jones et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
- (2011) Xiaotun Zhang et al. PLoS One
- Residual γH2AX foci as an indication of lethal DNA lesions
- (2010) Judit P Banáth et al. BMC CANCER
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
- (2010) Michel Bolla et al. LANCET ONCOLOGY
- Use of γH2AX and Other Biomarkers of Double-Strand Breaks During Radiotherapy
- (2010) Ali Sak et al. SEMINARS IN RADIATION ONCOLOGY
- H2AX Expression in Tumors Exposed to Cisplatin and Fractionated Irradiation
- (2009) C. A. Banuelos et al. CLINICAL CANCER RESEARCH
- DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
- (2009) Jason M D'Antonio et al. ENDOCRINE-RELATED CANCER
- Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials
- (2008) Stanley K. Liu et al. CANCER AND METASTASIS REVIEWS
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Use of the Rad51 promoter for targeted anti-cancer therapy
- (2008) C. M. Hine et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now